Study of 2LHERP® in Genital Herpes Infections

NCT04235322 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class

Stopped Labo'life decided to end prematurely HEARTH-GEN study from April 18th 2023 due to very low recruitment rates (6/100). Labo'life decided to focus all its efforts on another study using 2LHERP® in herpes treatment, called HEARTH-OF (NCT04065971)

Conditions

Interventions

Sponsor

Labo'Life